AMR diagnostic innovators get boost with launch of new Longitude Prize ”Sprint” Programme
The Longitude Prize, has launched a new programme of activity focused on accelerating innovation in diagnostic tests that are essential to managing the spread of antimicrobial resistance (AMR) worldwide. The new Longitude Prize Sprint programme consists of a series of free, deep-dive, technical workshops (delivered via webinar) with industry experts, plus a package of bespoke 1-to-1 expert support sessions for current Prize competitors. The programme will run until March 2021.
The Longitude Prize is a £10m prize fund that will reward a team of researchers that develops a rapid point-of-care diagnostic test that will help conserve antibiotics for generations to come.
This new programme of technical support responds to the need to drive support to the development of innovative diagnostic tests and investment opportunities for test developers. Without accurate, rapid diagnostic tests and best practice in antibiotic stewardship, we risk undermining the efficacy of the new drugs in the long-term and compromise our current stocks of antibiotics in the short-term. Longitude Prize Sprint aims to further build on the global efforts to augment innovative diagnostic product development in critical areas of AMR.
Though the focus of the diagnostic and pharmaceutical community is, by necessity, on dealing with the current pandemic, the threat of drug resistant infections has not abated. The Longitude Prize Sprint programme is targeted at driving forward the innovation we so urgently need to ensure the correct antibiotics are prescribed first time thanks to accurate, rapid and affordable diagnostic tests. Only then can we slow antimicrobial resistance and have confidence that existing and new antibiotics will be preserved for the long-term.
To find out more about the Longitude Prize Sprint Programme, visit: longitudeprize.org/sprint